Amicus Therapeutics

FOLD

Market cap $4.43B

Amicus stock soars 135.8% in six months as demand for marketed products grows. The company is set to be acquired by BioMarin for $4.8 billion.

Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum.

Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each share of Amicus that they own. KSF is seeking to determine whether this consideration and the process.

BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.

MILWAUKEE , Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Amicu.

BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.

BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.